Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Benefits of rituximab for elderly DLBCL patients

Raúl Córdoba • 22 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Anthracycline Antibodies R-CHOP Rituximab

Raul Cordoba, MD, PhD of University Hospital Fundación Jiménez Díaz, Madrid, Spain, outlines the survival benefit of rituximab with or without anthracyclines for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients over the age of 80 years. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023
2:08
The differences in outcomes and treatment in CLL patients with mutated and unmutated IGHV
Raúl Córdoba • 7 Oct 2023
2:12
Real-world safety and efficacy of first- and second-generation BTK inhibitors in CLL
Raúl Córdoba • 7 Oct 2023
2:20
Clinical relevance of geriatric assessment
Raúl Córdoba • 22 Jun 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals